1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet. 2005;365:1687-1717.
2. Mann GB, Fahey VD, Feleppa F, et al. Reliance on hormone receptor assays of surgical specimens may compromise outcomes in patients with breast cancer. J Clin Oncol.
3. Eifel P, Axelson JA, Costa J, et al. National Institutes of Health Consensus Development Conference Statement: adjuvant therapy for breast cancer, November 1-3, 2000. J Natl CancerInst.
4. Reebeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346:1616-1622.
5. International Breast Cancer Study Group. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93. J Clin Oncol. 2006;24:1332-1341.
6. Peto R, Davies C, on behalf of the ATLAS Collaboration. Atlas (Adjuvant Tamoxifen, Longer Against Shorter): International randomized trial of 10 versus 5 years of adjuvant tamoxifen among 11500 women-preliminary results. San Antonio Breast Cancer Symposium, December 2007, Late Breaking Abstract # 48.
7. Gray RG, Rea DW, Handley K, et al. aTTOM (adjuvant Tamoxifen—To Offer More?): randomized trial of 10 versus 5 years of adjuvant tamoxifen among 6,934 women with estrogen receptor-positive (ER+) or ER untested breast cancer: preliminary results. J Clin Oncol. 2008;26 (suppl):abstract 513,105.
8. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole
following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst.
9. Tetu B, Brisson J. Prognostic significance of the pattern of immunostaining and adjuvant therapy. Cancer. 1994;73:2358-2365.
10. Borg A, Baldetorp B, Ferno M, et al. ERBB2 amplification is assoicated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Lett.
11. Carlomagno C, Perrone F, Gall C, et al. C-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early stage breast cancer without axillary node metastases. J Clin Oncol.
12. Jimenez-Gordo AM, de las Heras B, Zamora P, et al. Failure of goserelin ovarian ablation in premenopausal women with breast cancer: two case reports. Gynecol Oncol.
13. Gnant M, Mlineritsch B, Schippinger W, et al. Adjuvant ovarian suppression combined with tamoxifen or anastrozole, alone or in combination with zolendronic acid, in premenopausal women with endocrine-responsive, stage I and II breast cancer: first efficacy results from ABCSG-12. J Clin Oncol. 2008;26:1006s.
14. Price KN, Goldhirsch A. Clinical trials update: International Breast Cancer Study Group. Breast Cancer Res.
15. LHRH-agonists in Early Breast Cancer Overview group. Use of luteinising-hormone-releasing hormone agonists as adjuvant treatment in premenopausal patients with hormone-receptor-positive breast cancer: a meta-analysis of individual patient data from randomized adjuvant trials. Lancet. 2007;369:1711-1723.
16. Goldhirsch A, Wood WC, Gelber RD, et al. Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007. Ann Oncol.
17. Davidson NE, O'Neill AM, Vukov AM, et al. Chemoendocrine therapy for premenopausal women with axillary lymph node-positive, steroid hormone receptor-positive breast cancer: results from INT 0101 (E5188). J Clin Oncol.
18. Love RR, Duc NB, Havighurst TC, et al. HER-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor positive premenopausal women with operable breast cancer. J Clin Oncol.
19. Pagani O, O'Neill A, Castiglione M, et al. Prognostic impact of amenorrhea after adjuvant chemotherapy in premenopausal breast cancer patients with axillary node involvement: results of International Breast Cancer Study Group (IBCSG) trial VI. Eur J Cancer.
20. Bines J, Oleske DM, Cobleigh MA. Ovarian function in premenopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol.
21. Smith IE, Dowsett M, Yap YS, et al. Adjuvant aromatase inhibitors for early breast cancer after chemotherapy-induced amenorrhea: caution and suggested guidelines. J ClinOncol.
22. Winer EP, Hudis C, Burstein HJ, et al. American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol.
23. Mauriac L. Keshaviah, Debled M, et al. Predictors of early relapse in postmenopausal women with hormone receptor-positive breast cancer in the BIG 1-98 trial. Ann Oncol.
24. International Breast Cancer Study Group. Toremifene and tamoxifen are equally effective for early stage breast cancer; first results of International Breast Cancer Study Group trials 12-93 and 14-93. Ann Oncol. 2004;15:1749-1759.
25. The ATAC (Arimidex, Tamoxifen Alone of in Combination) Trialists' Group. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomized trial. Lancet. 2002;359:2131-2139.
26. The Breast International Group (BIG) 1-98 Collaborative Group. A comparison of letrozole
and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med.
27. ATAC Trialists' Group. Effect of anastrozole and tamoxifen as adjuvant treatment for early stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol. 2008;9:45-53.
28. Coates AS, Keshaviah A, Thurlimann B, et al. Five years of letrozole
compared with tamoxifen as initial adjuvant therapy for postmenopausal women with enodcrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol.
29. Kaufmann M, Jonat W, Hilfrich J, et al. on behalf of the German Adjuvant Breast Cancer Group. Survival benefit of switching to anastrozole after 2 years treatment with tamoxifen versus continued tamoxifen therapy: the ARNA 95 study. J Clin Oncol. 2006;24:14S; Abstract 547.
30. Coombes RC, Hall E, Gibson LJ, et al. on behalf of the Intergroup Exemestane Study. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med.
31. Jakesz R, Jonat W, Gnant M, et al. on behalf of the ABCSG, the GABG. Switching of postmenopausal women with endocrine responsive early breast cancer to anastrozole after 2 years adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet.
32. Boccardo F, Rubagotti A, Puntoni M, et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole Trial. J Clin Oncol. 2005;23: 5148-5147.
33. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years of tamoxifen treatment (Intergroup Exemestane Study): a randomized controlled trial. Lancet 2007;369:559-570. Erratum in Lancet. 2007;369:906.
34. Jonat W, Ganant M, Boccardo F, et al. Effectiveness of switching from adjuvant tamoxifen to anastrozole in postmenopausal women with hormone-sensitive early-stage breast cancer: a meta analysis. Lancet Oncol.
35. Goss PE, Ingle JN, Martine S, et al. A randomized trial of letrozole
in postmenopausal women after 5 years of tamoxifen for early stage breast cancer. N Engl J Med.
36. Albain KS, Green SJ, Ravdin PM, et al. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). Proc Am Soc Clin Oncol. 2002;21:37a.
37. IBIS Investigators. First results from the International Breast Cancer Intervention Study (IBIS-1): a randomized prevention trial. Lancet. 2002;360: 817-824.
38. Braithwaite RS, Chlebowski RT, Lau J, et al. Meta-analysis of vascular and neoplastic events associated with tamoxifen. J Gen Intern Med.
39. Cuppone F, Bria E, Verma S, et al. Do adjuvant aromatase inhibitors increase the cardiovascular risk in postmenopausal women with early breast cancer? Cancer.
40. Goetz MP, Knox SK, Suman VJ, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat
41. Partridge AH, Wang PS, Winer E, et al. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol.
42. Hillner BE, Ingle JN, Chlebowski RT, et al. American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer. J Clin Oncol.
43. Gnant MF, Mlineritsch B, Luschin-Ebengreuth G, et al. Zolendronic acid prevents cancer treatment induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Study Group. J Clin Oncol.
44. Brufsky A, Bundred N, Coleman R, et al. An Integrated analysis of zolendronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole